A review of six placebo-controlled scientific trials with one,134 total contributors concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) were being connected with a larger normal advancement around the Ashworth scale for spasticity in several sclerosis patients compared with placebo, Despite the fact that this did not get to statistic